Earnings 06 Apr: GeNeuro GNRO.PA EURONEXT pre-market 03 Apr 2026: readout risk

We open pre-market for GNRO.PA stock with the company set to report results after the bell on 06 Apr 2026. GeNeuro SA trades at €0.031 with a one-day range €0.03–€0.03 and volume near 67,784 shares. The upcoming earnings and a potential temelimab readout are the main short-term catalysts for a thinly traded biotech listed on EURONEXT in Europe.

Earnings setup and timeline for GNRO.PA stock

GeNeuro (GNRO.PA) announces financials and program updates on 06 Apr 2026. Investors should expect commentary on cash burn and clinical milestones tied to temelimab. The official earnings announcement time is scheduled at 08:00 ET, which equates to after European trading hours.

The earnings event is the main catalyst. For a small-cap biotech, clinical readouts and cash guidance typically drive intraday moves in pre- and post-market sessions.

Price, liquidity and immediate market snapshot

GNRO.PA stock trades at €0.031 with previous close €0.03, day low €0.03 and day high €0.03. Market cap stands at €0.91M and shares outstanding are 29,486,556. Average daily volume is 154,310; current volume 67,784 shows below-average liquidity.

Low liquidity often amplifies post-earnings volatility. Expect wide spreads and rapid moves if the company releases unexpected clinical or cash updates.

Clinical program: why temelimab matters to GNRO.PA earnings

Temelimab is GeNeuro’s lead asset. The drug completed a Phase IIb trial in multiple sclerosis and has ongoing studies in type 1 diabetes and other indications. A positive development or clear regulatory pathway could materially change valuation expectations.

Investors should watch language on efficacy signals, enrollment updates, and any partnership or licensing interest. Those items usually shape short-term analyst re-ratings for GNRO.PA stock.

Financials, ratios and valuation for GNRO.PA stock

Trailing EPS is -0.59 and reported PE is negative (-0.05). Cash per share is €0.074 and the current ratio is 0.37, indicating tight liquidity. Enterprise value is €12.45M reflecting debt and market cap dynamics.

At this stage GeNeuro shows negative earnings and negative free cash flow per share. Valuation remains speculative and hinges on clinical and financing outcomes rather than revenue multiples.

Technical and sector context for GNRO.PA stock

Short-term technicals show RSI near 53.72 and ADX at 52.46, implying a recent trend strength signal. The 50-day price average is €0.033 and the 200-day average is €0.044, both above current price.

Sector peers in Healthcare and Biotechnology have stronger liquidity and higher average P/E. GNRO.PA’s tiny market cap and volume set it apart from typical sector comparables and increase event risk.

Meyka AI grade, targets and analyst-style guidance

Meyka AI rates GNRO.PA with a score out of 100: 60.92 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Price targets we view as scenario-driven: conservative €0.02, base €0.045, bull €0.10. No formal analyst consensus is available. For trading, treat GNRO.PA as high volatility and event-driven.

Final Thoughts

Key takeaways for GNRO.PA stock ahead of the 06 Apr earnings are clear. GeNeuro trades at €0.031 with low liquidity and an enterprise value of €12.45M. The upcoming earnings and any temelimab readout will be the primary drivers of price action. Meyka AI’s forecast model projects a 12-month base price of €0.050, implying upside of 62.34% versus the current price €0.031, while acknowledging a wide range of outcomes. Forecasts are model-based projections and not guarantees. Given negative EPS -0.59, tight cash metrics, and event risk, investors should treat GNRO.PA stock as speculative and size positions accordingly. For more company details visit the official GeNeuro site and see our platform page for live updates at Meyka GNRO.PA. Meyka AI provides this as AI-powered market analysis and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.